KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares RepurchasedShort-Term Debt repayments
Ratios

Pacira BioSciences (PCRX) Leases (2019 - 2025)

Pacira BioSciences (PCRX) has 7 years of Leases data on record, last reported at $41.8 million in Q4 2025.

  • For Q4 2025, Leases fell 15.13% year-over-year to $41.8 million; the TTM value through Dec 2025 reached $41.8 million, down 15.13%, while the annual FY2025 figure was $41.8 million, 15.13% down from the prior year.
  • Leases reached $41.8 million in Q4 2025 per PCRX's latest filing, down from $44.3 million in the prior quarter.
  • Across five years, Leases topped out at $76.4 million in Q4 2021 and bottomed at $41.8 million in Q4 2025.
  • Average Leases over 5 years is $61.7 million, with a median of $64.6 million recorded in 2023.
  • Peak YoY movement for Leases: soared 93.78% in 2021, then decreased 19.33% in 2024.
  • A 5-year view of Leases shows it stood at $76.4 million in 2021, then fell by 7.24% to $70.9 million in 2022, then dropped by 13.91% to $61.0 million in 2023, then fell by 19.33% to $49.2 million in 2024, then dropped by 15.13% to $41.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Leases were $41.8 million in Q4 2025, $44.3 million in Q3 2025, and $46.5 million in Q2 2025.